Descripción del proyecto
Administración de fármacos para el sistema nervioso centra a través de la cavidad nasal
El tratamiento de los trastornos del sistema nervioso central (SNC), como la esclerosis múltiple, sigue siendo un reto médico importante porque la mayoría de los fármacos, incluidos los anticuerpos, no consiguen atravesar eficazmente la barrera hematoencefálica (BHE). La administración de fármacos por vía nasal llega al SNC sorteando la BHE, lo que ofrece una estrategia prometedora y no invasiva para tratar trastornos del SNC. El equipo del proyecto N2B-patch, financiado con fondos europeos, pretende desarrollar un producto sanitario innovador que facilite la administración de fármacos a través de la cavidad nasal. El producto constará de partículas poliméricas biodegradables incrustadas en una matriz de hidrogel. La formulación cargada de fármaco proporcionará un recubrimiento sensible al pH para garantizar la adhesión específica al epitelio olfativo y aumentar la biodisponibilidad del fármaco en el SNC.
Objetivo
The overall aim of N2B-patch is the development of a new innovative N2B drug delivery technology based on the synthesis of a biomaterial-based innovative galenic formulation that will be applied with the aid of a novel medical device equipped with a container closure system (CCS) as a hydrogel patch to the nasal olfactory region for the chronic treatment of MS. The galenic formulation will consist of drug loaded biodegradable polymer particles (e.g. chitosan, polylactic-co-glycolic acid, PLGA) embedded into a biodegradable hydrogel matrix (e.g. hyaluronic acid (HA)-based) to be deposited as a patch onto the olfactory region. A pH-sensitive, mucoadhesive particle coating (e.g. chitosan, chitosan derivatives) will ensure an environment-specific adhesion to the olfactory epithelium. This novel technology will largely enhance the controlled and sustainable delivery of drugs and increase the drug bioavailabilty to the CNS. NogoA antagonist NG-101 will be used as an active pharmaceutical ingredient (API). Proof of concept studies and initial clinical data have proven the enormous potential of blocking NogoA for spinal cord remyelation and axonal integrity. However, monoclonal antibodies (mAb) like NG-101, do not sufficiently cross the BBB. The sustainable and controlled release of NG-101 to the CNS will be achieved via the transport of embedded polymer particles to the olfactory epithelium, the subsequent release of API and permeation through the olfactory region, the only part of the nasal epithelium which is in direct contact with the brain. The direct transport route from the nasal cavity to the brain, bypassing the BBB, offers an exciting mode of central nervous system (CNS) drug delivery not only for demyelinating disorders but also for other CNS indications, e.g. stroke, neurodegenerative diseases or tumours. The proposed new innovative N2B drug delivery platform is a practical, safe, and minimally invasive technology. It will be exploited for NG-101 and has the potential to be implemented with other APIs with a low CNS bioavailability.
Ámbito científico
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesbasic medicineneurologymultiple sclerosis
- medical and health sciencesbasic medicinepharmacology and pharmacypharmacokinetics
- medical and health sciencesbasic medicineneurologystroke
- medical and health sciencesmedical biotechnologyimplants
Palabras clave
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-NMBP-2016-two-stage
Régimen de financiación
RIA - Research and Innovation actionCoordinador
80686 Munchen
Alemania